請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/61905
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 陳建煒(Kin-Wei Arnold Chan) | |
dc.contributor.author | Chia-Hung Liu | en |
dc.contributor.author | 劉家鴻 | zh_TW |
dc.date.accessioned | 2021-06-16T13:18:06Z | - |
dc.date.available | 2020-08-27 | |
dc.date.copyright | 2020-08-27 | |
dc.date.issued | 2020 | |
dc.date.submitted | 2020-06-19 | |
dc.identifier.citation | 1. Shimabukuro TT, Nguyen M, Martin D, DeStefano F. Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS). Vaccine. 2015;33(36):4398-405. 2. Intussusception among recipients of rotavirus vaccine--United States, 1998-1999. MMWR Morb Mortal Wkly Rep. 1999;48(27):577-81. 3. Iskander JK, Miller ER, Chen RT. The role of the Vaccine Adverse Event Reporting system (VAERS) in monitoring vaccine safety. Pediatr Ann. 2004;33(9):599-606. 4. Baggs J, Gee J, Lewis E, Fowler G, Benson P, Lieu T, et al. The Vaccine Safety Datalink: a model for monitoring immunization safety. Pediatrics. 2011;127 Suppl 1:S45-53. 5. Yu O, Bohlke K, Hanson CA, Delaney K, Rees TG, Zavitkovsky A, et al. Hepatitis B vaccine and risk of autoimmune thyroid disease: a Vaccine Safety Datalink study. Pharmacoepidemiol Drug Saf. 2007;16(7):736-45. 6. Nguyen M, Ball R, Midthun K, Lieu TA. The Food and Drug Administration's Post-Licensure Rapid Immunization Safety Monitoring program: strengthening the federal vaccine safety enterprise. Pharmacoepidemiol Drug Saf. 2012;21 Suppl 1:291-7. 7. Yih WK, Maro JC, Nguyen M, Baker MA, Balsbaugh C, Cole DV, et al. Assessment of Quadrivalent Human Papillomavirus Vaccine Safety Using the Self-Controlled Tree-Temporal Scan Statistic Signal-Detection Method in the Sentinel System. Am J Epidemiol. 2018;187(6):1269-76. 8. 藥物安全監視管理辦法 [Available from: http://law.moj.gov.tw/LawClass/LawAll.aspx?PCode=L0030050.] 9. Guidance for Good Pharmacovigilance Practice [Available from: https://www.fda.gov.tw/upload/133/2014122815052015960.pdf.] 10. 衛生福利部食品藥物管理署. 藥品不良反應通報 [Available from: https://www.fda.gov.tw/tc/siteContent.aspx?sid=4240. 11. 衛生福利部食品藥物管理署. 藥物安全監視名單 [Available from: https://www.fda.gov.tw/tc/site.aspx?sid=38.] 12. Omer SB, Salmon DA, Orenstein WA, deHart MP, Halsey N. Vaccine refusal, mandatory immunization, and the risks of vaccine-preventable diseases. The New England journal of medicine. 2009;360(19):1981-8. 13. Wakefield AJ, Murch SH, Anthony A, Linnell J, Casson DM, Malik M, et al. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet (London, England). 1998;351(9103):637-41. 14. Spencer JP, Trondsen Pawlowski RH, Thomas S. Vaccine Adverse Events: Separating Myth from Reality. American family physician. 2017;95(12):786-94. 15. Heininger U, Seward JF. Varicella. Lancet (London, England). 2006;368(9544):1365-76. 16. Chaves SS, Gargiullo P, Zhang JX, Civen R, Guris D, Mascola L, et al. Loss of vaccine-induced immunity to varicella over time. The New England journal of medicine. 2007;356(11):1121-9. 17. Takahashi M, Okuno Y, Otsuka T, Osame J, Takamizawa A. Development of a live attenuated varicella vaccine. Biken J. 1975;18(1):25-33. 18. Chuang YY, Huang YC, Chang LY, Chiu CH, Lin TY. Complications of varicella requiring hospitalisation before and after the introduction of varicella vaccine in a children's hospital in Taiwan. European journal of pediatrics. 2003;162(2):112-3. 19. Lin MR, Kuo CC, Hsieh YC, Huang YL, Huang YC, Hung YT, et al. Seroepidemiology of varicella among elementary school children in northern Taiwan. Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi. 2015. 20. Chang LY, Huang LM, Chang IS, Tsai FY. Epidemiological characteristics of varicella from 2000 to 2008 and the impact of nationwide immunization in Taiwan. BMC infectious diseases. 2011;11:352. 21. Definition and Application of Terms for Vaccine Pharmacovigilance. International Organizations of Medical Sciences; 2012. 22. Weibel RE, Neff BJ, Kuter BJ, Guess HA, Rothenberger CA, Fitzgerald AJ, et al. Live attenuated varicella virus vaccine. Efficacy trial in healthy children. N Engl J Med. 1984;310(22):1409-15. 23. Englund JA, Suarez CS, Kelly J, Tate DY, Balfour HH, Jr. Placebo-controlled trial of varicella vaccine given with or after measles-mumps-rubella vaccine. J Pediatr. 1989;114(1):37-44. 24. Kuter BJ, Weibel RE, Guess HA, Matthews H, Morton DH, Neff BJ, et al. Oka/Merck varicella vaccine in healthy children: final report of a 2-year efficacy study and 7-year follow-up studies. Vaccine. 1991;9(9):643-7. 25. White CJ, Kuter BJ, Hildebrand CS, Isganitis KL, Matthews H, Miller WJ, et al. Varicella vaccine (VARIVAX) in healthy children and adolescents: results from clinical trials, 1987 to 1989. Pediatrics. 1991;87(5):604-10. 26. Clements DA, Armstrong CB, Ursano AM, Moggio MM, Walter EB, Wilfert CM. Over five-year follow-up of Oka/Merck varicella vaccine recipients in 465 infants and adolescents. Pediatr Infect Dis J. 1995;14(10):874-9. 27. Kuter BJ, Ngai A, Patterson CM, Staehle BO, Cho I, Matthews H, et al. Safety, tolerability, and immunogenicity of two regimens of Oka/Merck varicella vaccine (Varivax) in healthy adolescents and adults. Oka/Merck Varicella Vaccine Study Group. Vaccine. 1995;13(11):967-72. 28. Ramkissoon A, Coovadia HM, Jugnundan P, Haffejee IE, Meurice F, Vandevoorde D. Immunogenicity and safety of a live attenuated varicella vaccine in healthy Indian children aged 9-24 months. S Afr Med J. 1995;85(12):1295-8. 29. Ngai AL, Staehle BO, Kuter BJ, Cyanovich NM, Cho I, Matthews H, et al. Safety and immunogenicity of one vs. two injections of Oka/Merck varicella vaccine in healthy children. Pediatr Infect Dis J. 1996;15(1):49-54. 30. Varis T, Vesikari T. Efficacy of high-titer live attenuated varicella vaccine in healthy young children. J Infect Dis. 1996;174 Suppl 3:S330-4. 31. Lau YL, Vessey SJ, Chan IS, Lee TL, Huang LM, Lee CY, et al. A comparison of safety, tolerability and immunogenicity of Oka/Merck varicella vaccine and VARILRIX in healthy children. Vaccine. 2002;20(23-24):2942-9. 32. Kreth HW, Hoeger PH. Safety, reactogenicity, and immunogenicity of live attenuated varicella vaccine in children between 1 and 9 years of age with atopic dermatitis. European journal of pediatrics. 2006;165(10):677-83. 33. Pileggi GS, de Souza CB, Ferriani VP. Safety and immunogenicity of varicella vaccine in patients with juvenile rheumatic diseases receiving methotrexate and corticosteroids. Arthritis care research. 2010;62(7):1034-9. 34. Chaves SS, Haber P, Walton K, Wise RP, Izurieta HS, Schmid DS, et al. Safety of varicella vaccine after licensure in the United States: experience from reports to the vaccine adverse event reporting system, 1995-2005. J Infect Dis. 2008;197 Suppl 2:S170-7. 35. Goulleret N, Mauvisseau E, Essevaz-Roulet M, Quinlivan M, Breuer J. Safety profile of live varicella virus vaccine (Oka/Merck): five-year results of the European Varicella Zoster Virus Identification Program (EU VZVIP). Vaccine. 2010;28(36):5878-82. 36. Galea SA, Sweet A, Beninger P, Steinberg SP, Larussa PS, Gershon AA, et al. The safety profile of varicella vaccine: a 10-year review. J Infect Dis. 2008;197 Suppl 2:S165-9. 37. Black S, Shinefield H, Ray P, Lewis E, Hansen J, Schwalbe J, et al. Postmarketing evaluation of the safety and effectiveness of varicella vaccine. Pediatr Infect Dis J. 1999;18(12):1041-6. 38. Donahue JG, Kieke BA, Yih WK, Berger NR, McCauley JS, Baggs J, et al. Varicella vaccination and ischemic stroke in children: is there an association? Pediatrics. 2009;123(2):e228-34. 39. Macartney KK, Gidding HF, Trinh L, Wang H, McRae J, Crawford N, et al. Febrile seizures following measles and varicella vaccines in young children in Australia. Vaccine. 2015;33(11):1412-7. 40. Chen RT, Glasser JW, Rhodes PH, Davis RL, Barlow WE, Thompson RS, et al. Vaccine Safety Datalink project: a new tool for improving vaccine safety monitoring in the United States. The Vaccine Safety Datalink Team. Pediatrics. 1997;99(6):765-73. 41. Schink T, Holstiege J, Kowalzik F, Zepp F, Garbe E. Risk of febrile convulsions after MMRV vaccination in comparison to MMR or MMR+V vaccination. Vaccine. 2014;32(6):645-50. 42. Geier DA, Kern JK, Homme KG, Geier MR. Thimerosal exposure and disturbance of emotions specific to childhood and adolescence: A case-control study in the Vaccine Safety Datalink (VSD) database. Brain injury. 2017;31(2):272-8. 43. Farrington CP. Relative incidence estimation from case series for vaccine safety evaluation. Biometrics. 1995;51(1):228-35. 44. Farrington CP, Nash J, Miller E. Case series analysis of adverse reactions to vaccines: a comparative evaluation. American journal of epidemiology. 1996;143(11):1165-73. 45. Whitaker HJ, Farrington CP, Spiessens B, Musonda P. Tutorial in biostatistics: the self-controlled case series method. Stat Med. 2006;25(10):1768-97. 46. Farrington CP, Anaya-Izquierdo K, Whitaker HJ, Hocine MN, Douglas I, Smeeth L. Self-Controlled Case Series Analysis With Event-Dependent Observation Periods. Journal of the American Statistical Association. 2011;106(494):417-26. 47. Whitaker HJ, Hocine MN, Farrington CP. The methodology of self-controlled case series studies. Statistical methods in medical research. 2009;18(1):7-26. 48. Maclure M, Fireman B, Nelson JC, Hua W, Shoaibi A, Paredes A, et al. When should case-only designs be used for safety monitoring of medical products? Pharmacoepidemiology and drug safety. 2012;21 Suppl 1:50-61. 49. Nordmann S, Biard L, Ravaud P, Esposito-Farese M, Tubach F. Case-only designs in pharmacoepidemiology: a systematic review. PloS one. 2012;7(11):e49444. 50. Gault N, Castaneda-Sanabria J, Guillo S, Foulon S, Tubach F. Underuse of self-controlled designs in pharmacoepidemiology in electronic healthcare databases: a systematic review. Pharmacoepidemiology and drug safety. 2016;25(4):372-7. 51. Gault N, Castaneda-Sanabria J, De Rycke Y, Guillo S, Foulon S, Tubach F. Self-controlled designs in pharmacoepidemiology involving electronic healthcare databases: a systematic review. BMC medical research methodology. 2017;17(1):25. 52. Weldeselassie YG, Whitaker HJ, Farrington CP. Use of the self-controlled case-series method in vaccine safety studies: review and recommendations for best practice. Epidemiology and infection. 2011;139(12):1805-17. 53. Glanz JM, McClure DL, Xu S, Hambidge SJ, Lee M, Kolczak MS, et al. Four different study designs to evaluate vaccine safety were equally validated with contrasting limitations. Journal of clinical epidemiology. 2006;59(8):808-18. 54. Baker MA, Lieu TA, Li L, Hua W, Qiang Y, Kawai AT, et al. A vaccine study design selection framework for the postlicensure rapid immunization safety monitoring program. American journal of epidemiology. 2015;181(8):608-18. 55. Almenoff J, Tonning JM, Gould AL, Szarfman A, Hauben M, Ouellet-Hellstrom R, et al. Perspectives on the use of data mining in pharmaco-vigilance. Drug Saf. 2005;28(11):981-1007. 56. DeLoughery EP, Shatzel JJ. A comparative analysis of the safety profile of direct oral anticoagulants using the FDA adverse event reporting system. Eur J Haematol. 2019;103(1):43-6. 57. Yih WK, Maro JC, Nguyen M, Baker MA, Balsbaugh C, Cole DV, et al. Mini-Sentinel: Pilot Of Self-Controlled Tree-Temporal Scan Analysis For Gardasil Vaccine. The Sentinel System; 2016. 58. Maro MKRIJC. TreeScanTM: A Novel Data-Mining Tool for Medical Product Safety Surveillance. 33th International Conference on Pharmacoepidemiology Therapeutic Risk Management; Palais des congrès de Montréal2017. 59. Naus J. The Distribution of the Size of the Maximum Cluster of Points on a Line. Journal of The American Statistical Association - J AMER STATIST ASSN. 1965;60:532-8. 60. Hsing AW, Ioannidis JP. Nationwide Population Science: Lessons From the Taiwan National Health Insurance Research Database. JAMA Intern Med. 2015;175(9):1527-9. 61. Liu DP, Wang ET, Pan YH, Cheng SH. Innovative applications of immunisation registration information systems: example of improved measles control in Taiwan. Euro Surveill. 2014;19(50):20994. 62. Ma SJ, Li X, Xiong YQ, Yao AL, Chen Q. Combination Measles-Mumps-Rubella-Varicella Vaccine in Healthy Children: A Systematic Review and Meta-analysis of Immunogenicity and Safety. Medicine. 2015;94(44):e1721. 63. Rockville M. Healthcare Cost and Utilization Project: Agency for Healthcare Research and Quality; March 2020 [Available from: https://hcup-us.ahrq.gov/.] 64. Kathleen Stratton AF, Erin Rusch, and Ellen Wright Clayton. Adverse Effects of Vaccines: Evidence and Causality Institute of Medicine; Board on Population Health and Public Health Practice; Committee to Review Adverse Effects of Vaccines; 2012 [Available from: https://www.nap.edu/catalog/13164/adverse-effects-of-vaccines-evidence-and-causality.] 65. Dennehy PH, Reisinger KS, Blatter MM, Veloudis BA. Immunogenicity of subcutaneous versus intramuscular Oka/Merck varicella vaccination in healthy children. Pediatrics. 1991;88(3):604-7. 66. Shinefield HR, Black SB, Staehle BO, Matthews H, Adelman T, Ensor K, et al. Vaccination with measles, mumps and rubella vaccine and varicella vaccine: safety, tolerability, immunogenicity, persistence of antibody and duration of protection against varicella in healthy children. Pediatr Infect Dis J. 2002;21(6):555-61. 67. Parment PA, Svahn A, Ruden U, Brakenhielm G, Storsaeter J, Akesson L, et al. Immunogenicity and reactogenicity of a single dose of live attenuated varicella vaccine and a booster dose of measles-mumps-rubella vaccine given concomitantly at 12 years of age. Scand J Infect Dis. 2003;35(10):736-42. 68. Gatchalian S, Leboulleux D, Desauziers E, Bermal N, Borja-Tabora C. Immunogenicity and safety of a varicella vaccine, Okavax, and a trivalent measles, mumps and rubella vaccine, MMR-II, administered concomitantly in healthy Filipino children aged 12-24 months. Southeast Asian J Trop Med Public Health. 2003;34(3):589-97. 69. Ferrera G, Gajdos V, Thomas S, Tran C, Fiquet A. Safety of a refrigerator-stable varicella vaccine (VARIVAX) in healthy 12- to 15-month-old children: A randomized, double-blind, cross-over study. Hum Vaccin. 2009;5(7):455-60. 70. Marin M, Guris D, Chaves SS, Schmid S, Seward JF. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007;56(Rr-4):1-40. 71. Sharrar RG, LaRussa P, Galea SA, Steinberg SP, Sweet AR, Keatley RM, et al. The postmarketing safety profile of varicella vaccine. Vaccine. 2000;19(7-8):916-23. 72. Mantadakis E, Farmaki E, Buchanan GR. Thrombocytopenic purpura after measles-mumps-rubella vaccination: a systematic review of the literature and guidance for management. J Pediatr. 2010;156(4):623-8. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/61905 | - |
dc.description.abstract | 背景 疫苗上市後的安全訊號(safety signals)偵測及精練(detection and refinement)面臨缺乏主動偵測及研究方法限制等問題。國內自2004年開始全面接種水痘疫苗,但目前國內外對水痘疫苗安全性研究並不多。本研究串連國內高涵蓋率的全民健保研究資料庫 (National Health Insurance Research Database)醫療照護記錄及全國預防接種資訊管理系統(National Immunization Information System),進行水痘疫苗上市後之主動偵測的資料庫探勘(data mining)及安全訊號之檢定。 研究方法 透過串連台灣全民健保研究資料庫的醫療照護記錄及全國預防接種資訊管理系統的疫苗資料,建立2004-2014年水痘疫苗接種世代。研究對象納入條件為12至35個月之幼童第一次接受水痘疫苗族群,排除同一天接受其他疫苗者。 資料庫探勘法以self-controlled tree-temporal scan statistic方式進行,疫苗注射後1-56天內急診及住院診斷納入潛在不良事件,事件發生前183天內無相似診斷。 安全訊號以Self-controlled risk interval design針對疫苗注射後預先設定的住院不良事件進行檢定(pneumonia, idiopathic thrombocytopenic purpura [ITP], menigitidis, encephalitits及ischemic stroke),定義新事件為發生前14天無相同診斷。危險期間為疫苗接種後1-42天,對照期間為43-84天,同時校正二個時間變量:年齡及季節。以Conditional Poisson regression比較危險期間及對照期間內不良事件之發生率(incidence rate)。 結果 2004年1月至2014年9月,在排除872,600位同一天接受其他疫苗後,共有1,194,189位僅接受單一水痘疫苗接種之幼童進入主要分析。 資料庫探勘發現五個statistical signals:fever in days 1-6 (relative risk (RR) 1.24, p<0.001)、gastritis and duodenitis in days 1-2 (RR 1.9, p<0.001)、acute respiratory infections in days 1-6 (RR 1.43, p<0.001)、varicella infection (RR 4.95, p<0.001)及nausea and vomiting in days 1-3 (RR 1.4, p=0.042),安全訊號皆發生在疫苗注射後10天內。 疫苗注射後1-42天內,未觀察到特定不良事件有增加危險,但觀察到immunosuppressive幼童有pneumonia上升的風險(adjusted incidence rate ratio [aIRR] 1.29; 95% confidence interval [CI], 1.02-1.62)。另外,36-42天有pneumonia 發生上升的危險 (aIRR 1.10; 95% CI, 1.02-1.18)。 結論 利用台灣全民健保資料庫的醫療照護記錄及全國預防接種資訊管理系統資料,有助於疫苗上市後安全性研究之進行。我們並未偵測到水痘疫苗注射後有未知的安全訊號。對於已知可能潛在不良反應,觀察到疫苗注射第六週有肺炎上升的趨勢。 | zh_TW |
dc.description.abstract | Background Even though the current proof of varicella vaccine safety is made of from the results of premarketing clinical trials and rare reported severe adverse events, it still needs the comprehensive epidemiologic evidence of post-marketing study to support the evidence of safety of universal varicella vaccination. With the linkage of the Taiwan National Health Insurance data and the National Immunization Information System, we performed active safety surveillance after varicella immunization and evaluated the association of pre-specified adverse events and varicella vaccines. Method The study population was 12- to 35-month children who received varicella vaccine during 2004 January through 2014 September. In this post-vaccination surveillance study with data mining method, we collected all incident ICD-9-CM diagnoses in emergency or inpatient department occurring 1–56 days after varicella vaccination. We used TreeScan in a conditioned self-controlled tree-temporal method to explore clustering events in groups with potential temporal risk intervals. The comparison interval consisted of days outside the risk interval. The self-controlled risk interval design compared the incidence of pre-specified outcomes of interest during a risk interval of 1-42 days post-vaccination and a control interval of days 43-84. The outcomes of interest were defined as admitted pneumonia, idiopathic thrombocytopenic purpura, meningitis, encephalitis, and ischemic stroke, as well as fracture as a negative control. Conditional Poisson regression was used to assess the incidence rate ratio (IRR) with adjustments for age and seasonal effects. Result Of the 2,003,861 children receiving varicella vaccines, 1,194,189 (59.6%) children who did not receive other vaccines at the same time. Among them, there were 130,617 events occurring in 56 days after vaccination. We identified 9 alerting nodes with clustering features using TreeScan. The alerting nodes were then categorized into four safety signals: fever at day 1-6 (ICD-9 780.6, relative risk (RR) 1.24, p<0.001), gastritis and duodenitis at day 1-2 (ICD-9 535.00, RR 1.79, p<0.001), acute upper respiratory infections at day 1-5 (ICD-9 465.9, RR 1.62, p=0.006), and varicella infection without mention of complication at day 1-9 (ICD- 052.9, RR 4.96, p<0.001). All these signals and their risk periods have been identified in previous clinical trials and surveillance studies. In self-controlled risk interval study, there was no increase in the risk for ITP (aIRR 1.00; 95% CI, 0.76-1.33), meningitis (aIRR 1.21; 95% CI, 0.49-2.95), encephalitis (aIRR 1.00; 95% CI, 0.62-1.60), or ischemic stroke (aIRR 1.24; 95% CI, 0.31-4.95). A clustering feature with pneumonia was detected during days 36-42 post-vaccination (aIRR 1.10; 95% CI, 1.02 -1.18) and in children with immunosuppression during days 1-42 post-vaccination (aIRR 1.29; 95%CI, 1.02-1.62). Conclusion We did not detect unexpected acute medical events in cluster after mass varicella vaccination in Taiwan. A slightly increase in the risk of incidental pneumonia associated with varicella vaccine was observed in the 6th week after immunization. | en |
dc.description.provenance | Made available in DSpace on 2021-06-16T13:18:06Z (GMT). No. of bitstreams: 1 U0001-1906202020232300.pdf: 4990640 bytes, checksum: e5924c5291fa4d4fc23e71766966821e (MD5) Previous issue date: 2020 | en |
dc.description.tableofcontents | 口試委員會審定書 i 謝辭 ii 第一章 前言 1 1.1 疫苗安全性研究 1 1.3 國內疫苗上市後安全監測機制 3 1.4 國內水痘疫苗政策及水痘流行病學 4 第二章 水痘疫苗安全性之文獻回顧 6 2.1 水痘疫苗安全性研究 6 2.1.1 隨機分派對照實驗(randomized controlled trials) 6 2.1.2 疫苗不良事件通報系統 7 2.1.3 資料庫研究 8 2.2 利用資料庫進行安全性研究之方法 9 2.2.1 傳統觀察性研究 9 2.2.2 病例系列分析 11 2.2.3 資料庫探勘(Data mining) 13 2.2.4 樹狀基礎掃描統計法(Tree-based scan statistics) 14 第三章 研究目的及架構 18 第四章 研究材料及方法 19 4.1 疫苗暴露定義(Ascertainment of vaccine exposure) 19 4.2 結果定義(Outcome definition) 19 4.2.1 資料庫探勘 19 4.2.1 疫苗及已知潛在不良事件之相關性 20 4.3 統計分析(Statistical analysis) 20 4.3.1 資料庫探勘 21 4.3.2 水痘疫苗及已知潛在不良反應之相關性 22 第五章 結果 24 5.1 水痘疫苗世代 24 5.2 資料庫探勘 24 5.3 水痘疫苗及已知潛在不良事件之相關性 25 5.3.1 特定不良事件分佈(Event distribution) 25 5.3.2 特定不良事件發生比(Incidence rate ratio of outcomes of interest) 26 5.3.3 Subgroup analysis and sensitivity analysis 26 第六章 討論 28 6.1 資料庫探勘(data mining) 28 6.2 水痘疫苗及已知潛在不良事件之相關性 31 第七節 結論 33 參考文獻 34 附錄一 70 附錄二 71 | |
dc.language.iso | zh-TW | |
dc.title | 利用跨平台資料庫評估水痘疫苗之潛在風險 | zh_TW |
dc.title | Evaluating the safety of varicella vaccine by using information from different claims data | en |
dc.type | Thesis | |
dc.date.schoolyear | 108-2 | |
dc.description.degree | 博士 | |
dc.contributor.coadvisor | 季瑋珠(Wei-Chu Chie) | |
dc.contributor.oralexamcommittee | 黃婉婷(Wan-Ting Huang),杜裕康(Yu-Kang Tu),林先和(Hsien-Ho Lin) | |
dc.subject.keyword | 水痘疫苗,疫苗安全性評估,資料庫探勘,自我控制危險期間分析法,藥物流行病學, | zh_TW |
dc.subject.keyword | Varicella vaccine,data mining,self-control risk interval design,self-controlled tree-temporal scan statistic, | en |
dc.relation.page | 78 | |
dc.identifier.doi | 10.6342/NTU202001073 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2020-06-20 | |
dc.contributor.author-college | 公共衛生學院 | zh_TW |
dc.contributor.author-dept | 流行病學與預防醫學研究所 | zh_TW |
顯示於系所單位: | 流行病學與預防醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
U0001-1906202020232300.pdf 目前未授權公開取用 | 4.87 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。